Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters

Reuters

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters

Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters

Ver fuente original → ← Volver a noticias